Non smoking for successful aging: Therapeutic perspectives

Current Pharmaceutical Design

Volumn 16, Issue 7, 2010, Pages 775-782

  Nicita Mauro, V ^a,b   Maltese, G ^a,b   Nicita Mauro, C ^a,b   Lasco, A ^a,b   Basile, G ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Aging; Cigarette smoking; Elderly; Longevity; Smoking cessation

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DIGOXIN; METFORMIN; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM; PLACEBO; VARENICLINE; WARFARIN;

ABNORMAL DREAMING; AGING; CIGARETTE SMOKING; CLINICAL TRIAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; EVENING DOSAGE; HUMAN; INSOMNIA; LIFE EXPECTANCY; LUNG CANCER; MORNING DOSAGE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; SURVIVAL RATE; TRANSDERMAL PATCH; WITHDRAWAL SYNDROME; XEROSTOMIA;

AGING; HUMANS; LIFE EXPECTANCY; LONGEVITY; QUALITY OF LIFE; SMOKING; SMOKING CESSATION;

EID: 77950281947     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883552     Document Type: Review

References (71)

1. Bernhard D, Moser C, Backovic A, Wick G. Cigarette smoking - an aging accelerator? Exp Gerontol 2007; 42: 160-165
2. Nicita-Mauro V, Lo Balbo C, Mento A, Nicita-Mauro C, Maltese C, Basile G. Smoking, aging and the centenarians. Exp Gerontol 2008; 43: 95-101.
3. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-852
4. WHO. Report on the Global Tobacco Epidemic. The IMPOWER Package, Geneva, WHO 2008.
5. Vollset, ST, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med 2006; 144: 381-389
6. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J 2004; 328: 1519-1528
7. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994; 309: 901-911
8. Burns DM. Cigarettes and cigarette smoking. Clin Chest Med 1991; 12: 631-642
9. Pryor WA, Prier DG, Church DF. Electron-spin resonance study of mainstream and sidestream cigarette smoke: nature of the free radicals in gas phase smoke and in cigarette tar. Environ Health Perspect 1983; 47: 345-355
10. Nagy J, Demaster EG, Wittmann I, Shultz P, Raij L. Induction of endothelial cell injury by cigarette smoke. Endothelium 1997; 5: 251-263
11. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571
12. Pepine CJ, Schlaifer JD, Mancini GBJ, Pitt B, O'Neill BJ, Haber HE. Influence of smoking status on progression of endothelial dysfunction. TREND Investigators. Trial on reversing endothelial dysfunction. Clin Cardiol 1998; 21: 331-334
13. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43: 1731-1737
14. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Heavy and light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity. An in vivo and in vitro correlation. J Am Coll Cardiol 2002; 39: 1758-1763
15. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation 2005; 112: 489-497
16. Bernhard D, Csordas A, Handerson B, Rossmann A, Kind M, Wick G. Cigarette smoking metal-catalyzed protein oxidation leads to vascular endothelial cells contraction by depolymerization of microtubules. FASEB J 2005; 19: 1096-1107
17. Mazzone A, Cusa C, Mazzucchelli I, Vezzoli M, Ottini E, Ghio S, et al. Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. Clin Chem Lab Med 2001; 39: 822-826
18. Seltzer CC. Effect of smoking on blood pressure. Am Heart J 1974: 87: 558-564
19. Mann SJ, James GD, Wang RS, Pickering TG. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case control study. J Am Med Assoc 1991; 265: 2226-2228
20. Halperin RO, Gaziano JM, Sesso HD. Smoking and the risk incident hypertension in middle-aged and older men. Am J Hypertens 2008; 21: 148-152
21. Nicita-Mauro V. Smoking, calcium, calcium antagonists, and aging. Exp Gerontol 1990; 25: 393-399
22. Cole JW, Sorkin JD, Wozniak MA, Malarcher AM, Giles WH, Stern BJ, et al. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke 2008; 39: 2439-2443
23. Tengs TO, Osgood ND. The link between smoking and impotence: two decades of evidence. Prev Med 2001; 32: 447-452
24. Kodama M, Kaneko M, Aida M, Inoue F, Nakayama T, Akimoto H. Free radical chemistry of cigarette smoke and its implications in human cancer. Anticancer Res 1997; 17: 433-437
25. Demarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 2004; 567: 447-474
26. Sastre J, Pallardo FV, Vina J. The role of mitochondrial oxidative stress in aging. Free Radic Biol Med 2003; 35: 1-8.
27. Nyunoya T, Monick MM, Klingelhutz A, Yarovinsky TO, Cagley JR, Hunninghake GW. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol 2006; 35: 681-688
28. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. Br Med J 1997; 315: 841-846
29. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325
30. Kapoor D, Jones TH,. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol 2005; 152: 491-499
31. Meisinger C, Doring A, Thorand B, Lowel H. Association of cigarette smoking and tar and nicotine intake with development of type 2 diabetes mellitus in men and women from the general population: the MONICA/KORA Augsburg Cohort Study. Diabetologia 2006; 49: 1770-1776
32. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics 2006; 24: 319-334
33. Cong R, Zhou B, Sun Q, Gu H, Tang N, Wang B. Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 2008; 18: 647-656
34. Ferrite S, Santana V. Joint effects of smoking, noise exposure and age on hearing loss. Occup Med 2005; 55: 48-53.
35. Vennemann MM, Hummel T, Berger K. The association between smoking and smell and taste impairment in the general population. J Neurol 2008; 255: 1121-1126
36. Juan D, Zhou DH, Li J, Wang JY, Gao C, Chen M. A 2-year follow-up study of cigarette smoking and risk of dementia. Eur J Neurol 2004, 11: 277-282
37. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007; 166: 367-378
38. Riggs JE. Smoking and Alzheimer 2000's disease: protective effect or differential survival bias? Lancet 1993; 342: 793-794
39. Skoog L. Status of risk factors for vascular dementia. Neuroepidemiology 1998; 17: 2-9.
40. Esiri M, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999; 354: 919-920
41. Tzourio C, Rocca WA, Breteler MM, Baldereschi M, Dartigues JF, Lopez-Pousa S, et al. Smoking and Parkinson's disease. An age-dependent risk effect? The EUROPARKINSON Study Group. Neurology 1997; 49: 1267-1272
42. Nicita-Mauro V, Basile G, Maltese G, Nicita-Mauro C, Gangemi S, Caruso C. Smoking, Health and ageing. Immun Ageing 2008; 5: 10.
43. WHO. Available from: http://who.int/tobacco/en/.2004.
44. Taylor Jr DH, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002; 92: 990-996
45. Taylor HJ, Ebbert JO. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008; 121: S32-S42.
46. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guillox JP, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005; 436: 103-107
47. Foulds J. The Neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006; 60: 571-576
48. Stack NM. Smoking cessation: an overwiew of treatment options with a focus on varenicline. Pharmacotherapy 2007; 27: 1550-1557
49. European Medicines Agency. Human medicines. Available from: http://www.emea.europa.eu/index/indexh1.htm [accessed August 2007].
50. US Food and drug Administration. Electric Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: http://www.fda.gov/cder/ob/default.htm [accessed August 2007].
51. Fiore M, Jaèn C, Baker T, Bailey W, Benowitz N, Curry S, et al. Treating tobacco use and Dependence: 2008 update. Clinical Practice Guideline. US Department of Health and Human Services Public Health Service, 2008. Available from: www.ahrq.gov/path/tobacco. htm#Clinic.
52. Shiffman S, Di Martino M, Pillitteri J. The effectiveness of nicotine patch and nicotine lozenge in very heavy smokers. JSAT 2005; 28: 49-55.
53. Hajek P, West R, Foulds J, Nilsson F, Burrow S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159: 2033-2038
54. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl) 2006; 184: 637-644
55. Stead LF, Perera R, Bullen C, Mant D, Lancaster D. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 23: CD000146.
56. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; CD 000031.
57. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an 1/2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-3477
58. 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52: 985-994
59. Fiore MC, Bailey WC, Cohen SJ, Dorfman S, Goldstein M, Gretz E, et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. US Dept of Health and Human Services, Public Health Service 2000. Available from: http://www.surgeongeneral.gov/tobacco/default.htm.
60. Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol 2006; 46: 1234-1240
61. Nides M, Oncken C, Gonzales D, Rennard S, Watsky ES, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166: 1561-1568
62. Oncken C, Gonzales D, Nides M, Rennard S, Watsky ES, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-1577
63. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
64. 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
65. 2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29:1027-1039
66. 2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29:1040-1056
67. Eisenberg MJ, Filion KB, Yavin D, Bélisle Mottillo S, Joseph L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135-144
68. National Institute for Clinical Excellence (NICE). Update of Technology Appraisal for NRT and Bupropion: Possible extension? 2006. Available from: http://www.nice.org.uk/page.aspx?o=388602 [accessed July 2007].
69. Tønnesen P, Carrozzi L, Fagerström K, Gratziou C, Jimenez-Ruitz C, Nardini S, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417.
70. Reus VI, Smith BJ. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. Int J Clin Pract 2008; 62; 1753-1768
71. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klinger K, Van Mell G, et al. A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial. PLoS One 2008; 25: 3: e2547.